Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 28-year-old man with type 1 diabetes mellitus is receiving care in the intensive care unit for severe diabetic ketoacidosis. He is currently being managed with intravenous fluid resuscitation and a continuous intravenous regular insulin infusion. Arrange the following clinical milestones and monitoring-based interventions in the correct chronological sequence required for a safe transition to maintenance subcutaneous therapy.

  1. 1Hourly point-of-care testing reveals a capillary blood glucose decrease to 200 mg/dL.
  2. 2Append 5% dextrose to the maintenance intravenous fluids.
  3. 3Serial basic metabolic panels demonstrate closure of the anion gap to 10 mEq/L.
  4. 4Administer the scheduled dose of long-acting subcutaneous basal insulin.
  5. 5Discontinue the continuous intravenous regular insulin infusion two hours later.

Cevap

The correct sequence begins with monitoring blood glucose until it reaches 200 mg/dL, immediately adding dextrose to the IV fluids, continuing to monitor until the anion gap closes, administering subcutaneous insulin, and finally discontinuing the IV insulin infusion two hours later.
The standard protocol for managing diabetic ketoacidosis (DKA) requires rigorous sequential monitoring and treatment modification. Initially, IV fluids and an insulin infusion are started. Because glucose normalizes faster than the ketoacidosis resolves, when the blood glucose falls to 200 mg/dL, 5% dextrose must be added to the IV fluids. This prevents hypoglycemia and allows the insulin infusion to continue suppressing lipolysis and ketogenesis. The physician must then monitor serial basic metabolic panels until the anion gap closes (≤ 12 mEq/L), which signals the resolution of DKA. Once resolved, the transition to subcutaneous insulin is initiated by administering a long-acting basal dose. Finally, because subcutaneous insulin takes 1 to 2 hours to achieve therapeutic systemic absorption, the IV insulin infusion must be maintained for an overlapping 2-hour period before being discontinued to prevent a relapse of DKA.

Adım Adım Çözüm

1
Monitor capillary blood glucose hourly until it reaches the 200 mg/dL threshold.
Identifies the point where the patient is at risk for hypoglycemia if pure saline is continued.
Blood glucose typically normalizes much faster than the metabolic acidosis resolves.
2
Add 5% dextrose to the intravenous fluid regimen.
Maintains blood glucose levels in a safe range (150-200 mg/dL).
Allows the continuous insulin infusion to be maintained at a rate sufficient to clear ketones without inducing iatrogenic hypoglycemia.
3
Monitor serial chemistry panels every 2 to 4 hours to assess the anion gap.
Confirms the closure of the anion gap (typically ≤ 12 mEq/L) and normalization of bicarbonate.
Closure of the anion gap is the definitive marker that diabetic ketoacidosis has resolved and continuous IV insulin is no longer strictly required for ketone suppression.
4
Administer the first dose of subcutaneous basal insulin.
Begins the transition to long-term maintenance therapy.
Subcutaneous insulin must be given once the acidosis is resolved and the patient is preparing to resume an oral diet.
5
Maintain the IV insulin infusion for an additional 2 hours before discontinuing it.
Provides an insulin overlap.
Subcutaneous insulin has a delayed onset of action. The overlap prevents a window of insulin deficiency and subsequent rebound ketoacidosis.

Anahtar Kavram

Monitoring and Sequencing the Transition off Intravenous Insulin in Diabetic Ketoacidosis
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru